BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 12393437)

  • 1. Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome.
    Richardson PG; Murakami C; Jin Z; Warren D; Momtaz P; Hoppensteadt D; Elias AD; Antin JH; Soiffer R; Spitzer T; Avigan D; Bearman SI; Martin PL; Kurtzberg J; Vredenburgh J; Chen AR; Arai S; Vogelsang G; McDonald GB; Guinan EC
    Blood; 2002 Dec; 100(13):4337-43. PubMed ID: 12393437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in response without significant toxicity in a high-risk population.
    Richardson PG; Elias AD; Krishnan A; Wheeler C; Nath R; Hoppensteadt D; Kinchla NM; Neuberg D; Waller EK; Antin JH; Soiffer R; Vredenburgh J; Lill M; Woolfrey AE; Bearman SI; Iacobelli M; Fareed J; Guinan EC
    Blood; 1998 Aug; 92(3):737-44. PubMed ID: 9680339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of plasminogen activator inhibitor-1 (PAI-1) levels in the diagnosis of BMT-associated hepatic veno-occlusive disease and monitoring of subsequent therapy with defibrotide (DF).
    Kaleelrahman M; Eaton JD; Leeming D; Bowyer K; Taberner D; Chang J; Scarffe JH; Chopra R
    Hematology; 2003 Apr; 8(2):91-5. PubMed ID: 12745658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Defibrotide for the treatment of hepatic veno-occlusive disease: results of the European compassionate-use study.
    Chopra R; Eaton JD; Grassi A; Potter M; Shaw B; Salat C; Neumeister P; Finazzi G; Iacobelli M; Bowyer K; Prentice HG; Barbui T
    Br J Haematol; 2000 Dec; 111(4):1122-9. PubMed ID: 11167751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trial.
    Richardson PG; Soiffer RJ; Antin JH; Uno H; Jin Z; Kurtzberg J; Martin PL; Steinbach G; Murray KF; Vogelsang GB; Chen AR; Krishnan A; Kernan NA; Avigan DE; Spitzer TR; Shulman HM; Di Salvo DN; Revta C; Warren D; Momtaz P; Bradwin G; Wei LJ; Iacobelli M; McDonald GB; Guinan EC
    Biol Blood Marrow Transplant; 2010 Jul; 16(7):1005-17. PubMed ID: 20167278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Veno-occlusive disease of the liver in the absence of elevation in bilirubin in pediatric patients after hematopoietic stem cell transplantation.
    Myers KC; Dandoy C; El-Bietar J; Davies SM; Jodele S
    Biol Blood Marrow Transplant; 2015 Feb; 21(2):379-81. PubMed ID: 25300869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Defibrotide for Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome: Interim Results from a Treatment IND Study.
    Richardson PG; Smith AR; Triplett BM; Kernan NA; Grupp SA; Antin JH; Lehmann L; Shore T; Iacobelli M; Miloslavsky M; Hume R; Hannah AL; Nejadnik B; Soiffer RJ;
    Biol Blood Marrow Transplant; 2017 Jun; 23(6):997-1004. PubMed ID: 28285079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Escalation to High-Dose Defibrotide in Patients with Hepatic Veno-Occlusive Disease.
    Triplett BM; Kuttab HI; Kang G; Leung W
    Biol Blood Marrow Transplant; 2015 Dec; 21(12):2148-2153. PubMed ID: 26278046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Earlier defibrotide initiation post-diagnosis of veno-occlusive disease/sinusoidal obstruction syndrome improves Day +100 survival following haematopoietic stem cell transplantation.
    Richardson PG; Smith AR; Triplett BM; Kernan NA; Grupp SA; Antin JH; Lehmann L; Miloslavsky M; Hume R; Hannah AL; Nejadnik B; Soiffer RJ
    Br J Haematol; 2017 Jul; 178(1):112-118. PubMed ID: 28444784
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure.
    Richardson PG; Riches ML; Kernan NA; Brochstein JA; Mineishi S; Termuhlen AM; Arai S; Grupp SA; Guinan EC; Martin PL; Steinbach G; Krishnan A; Nemecek ER; Giralt S; Rodriguez T; Duerst R; Doyle J; Antin JH; Smith A; Lehmann L; Champlin R; Gillio A; Bajwa R; D'Agostino RB; Massaro J; Warren D; Miloslavsky M; Hume RL; Iacobelli M; Nejadnik B; Hannah AL; Soiffer RJ
    Blood; 2016 Mar; 127(13):1656-65. PubMed ID: 26825712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pooled analysis of Day 100 survival for defibrotide-treated patients with hepatic veno-occlusive disease/sinusoidal obstruction syndrome and ventilator or dialysis dependence following haematopoietic cell transplantation.
    Richardson PG; Smith AR; Kernan NA; Lehmann L; Soiffer RJ; Ryan RJ; Tappe W; Grupp S
    Br J Haematol; 2020 Aug; 190(4):583-587. PubMed ID: 32157682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Defibrotide for Treatment of Severe Veno-Occlusive Disease in Pediatrics and Adults: An Exploratory Analysis Using Data from the Center for International Blood and Marrow Transplant Research.
    Strouse C; Richardson P; Prentice G; Korman S; Hume R; Nejadnik B; Horowitz MM; Saber W
    Biol Blood Marrow Transplant; 2016 Jul; 22(7):1306-1312. PubMed ID: 27108694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Defibrotide for the Treatment of Hepatic Veno-Occlusive Disease: Final Results From the International Compassionate-Use Program.
    Corbacioglu S; Carreras E; Mohty M; Pagliuca A; Boelens JJ; Damaj G; Iacobelli M; Niederwieser D; Olavarría E; Suarez F; Ruutu T; Verdonck L; Hume R; Nejadnik B; Lai C; Finetto G; Richardson P
    Biol Blood Marrow Transplant; 2016 Oct; 22(10):1874-1882. PubMed ID: 27397724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Defibrotide in the treatment of children with veno-occlusive disease (VOD): a retrospective multicentre study demonstrates therapeutic efficacy upon early intervention.
    Corbacioglu S; Greil J; Peters C; Wulffraat N; Laws HJ; Dilloo D; Straham B; Gross-Wieltsch U; Sykora KW; Ridolfi-Lüthy A; Basu O; Gruhn B; Güngör T; Mihatsch W; Schulz AS
    Bone Marrow Transplant; 2004 Jan; 33(2):189-95. PubMed ID: 14661036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-Effectiveness of Defibrotide in the Prophylaxis of Veno-Occlusive Disease after Pediatric Allogeneic Stem Cell Transplantation.
    Pichler H; Horner K; Engstler G; Poetschger U; Glogova E; Karlhuber S; Martin M; Eibler W; Witt V; Holter W; Matthes-Martin S
    Biol Blood Marrow Transplant; 2017 Jul; 23(7):1128-1133. PubMed ID: 28359910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Defibrotide for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome following nontransplant-associated chemotherapy: Final results from a post hoc analysis of data from an expanded-access program.
    Kernan NA; Richardson PG; Smith AR; Triplett BM; Antin JH; Lehmann L; Messinger Y; Liang W; Hume R; Tappe W; Soiffer RJ; Grupp SA
    Pediatr Blood Cancer; 2018 Oct; 65(10):e27269. PubMed ID: 29873895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Veno-occlusive disease in pediatric patients affected by Wilms tumor.
    Cesaro S; Spiller M; Sartori MT; Alaggio R; Peruzzo M; Saggiorato G; Bisogno G
    Pediatr Blood Cancer; 2011 Aug; 57(2):258-61. PubMed ID: 21246705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial.
    Corbacioglu S; Cesaro S; Faraci M; Valteau-Couanet D; Gruhn B; Rovelli A; Boelens JJ; Hewitt A; Schrum J; Schulz AS; Müller I; Stein J; Wynn R; Greil J; Sykora KW; Matthes-Martin S; Führer M; O'Meara A; Toporski J; Sedlacek P; Schlegel PG; Ehlert K; Fasth A; Winiarski J; Arvidson J; Mauz-Körholz C; Ozsahin H; Schrauder A; Bader P; Massaro J; D'Agostino R; Hoyle M; Iacobelli M; Debatin KM; Peters C; Dini G
    Lancet; 2012 Apr; 379(9823):1301-9. PubMed ID: 22364685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Defibrotide in the prevention and treatment of veno-occlusive disease in autologous and allogeneic stem cell transplantation in children.
    Qureshi A; Marshall L; Lancaster D
    Pediatr Blood Cancer; 2008 Apr; 50(4):831-2. PubMed ID: 18286502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of veno-occlusive disease with defibrotide after allogeneic stem cell transplantation.
    Chalandon Y; Roosnek E; Mermillod B; Newton A; Ozsahin H; Wacker P; Helg C; Chapuis B
    Biol Blood Marrow Transplant; 2004 May; 10(5):347-54. PubMed ID: 15111934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.